Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-2 of 2

Sort by

Sort Order Select

Journal Articles

A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results

Keith W. Pratz, MD, Mohamad Cherry, MDMS, Jessica K. Altman, MD, Brenda W. Cooper, MD, Jose Carlos Cruz, MD, Joseph G. Jurcic, MD, Mark Levis, MD PhD, Tara Lin, MD, Alexander E. Perl, MD, Nikolai A. Podoltsev, MD PhD, Gary J. Schiller, MD, Jason E. Hill, PhD, Angela James, PhD, Qiaoyang Lu, MS, Ramon V. Tiu, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-137685

Published: 2020

Journal Articles

Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Treatment with Gilteritinib in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) with FLT3 Mutations

Mark J. Levis, MD, Alexander E. Perl, MD, Jessica K. Altman, MD, Jorge E. Cortes, MD, Catherine C. Smith, MD, Maria R. Baer, MD, David F. Claxton, MD, Joseph G. Jurcic, MD, Ellen K. Ritchie, MD, Stephen A. Strickland, MD, Raoul Tibes, MD PhD, Jason E. Hill, PhD, Matt Rosales, Erkut Bahceci, MD

Blood (2018) 132 (Supplement 1): 1458.

https://doi.org/10.1182/blood-2018-99-110971

Published: 2018